Wen-Kai Weng

2.2k total citations
25 papers, 1.4k citations indexed

About

Wen-Kai Weng is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Wen-Kai Weng has authored 25 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 9 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Wen-Kai Weng's work include CAR-T cell therapy research (7 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Wen-Kai Weng is often cited by papers focused on CAR-T cell therapy research (7 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Wen-Kai Weng collaborates with scholars based in United States, Germany and China. Wen-Kai Weng's co-authors include Randall Armstrong, Ute M. Moll, Stephen Yu, N D Marchenko, Walter Hanel, Suheng Xu, Youn H. Kim, J L Breslow, Sandra K. Erickson and D. L. Williams and has published in prestigious journals such as Journal of Clinical Investigation, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Wen-Kai Weng

22 papers receiving 1.3k citations

Peers

Countries citing papers authored by Wen-Kai Weng

Since Specialization

Citations

This map shows the geographic impact of Wen-Kai Weng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wen-Kai Weng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wen-Kai Weng more than expected).

Fields of papers citing papers by Wen-Kai Weng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wen-Kai Weng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wen-Kai Weng. The network helps show where Wen-Kai Weng may publish in the future.

Co-authorship network of co-authors of Wen-Kai Weng

This figure shows the co-authorship network connecting the top 25 collaborators of Wen-Kai Weng. A scholar is included among the top collaborators of Wen-Kai Weng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wen-Kai Weng. Wen-Kai Weng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy 2025 ·Blood Advances ·(unknown), (unknown), Bita Sahaf, Lekha Mikkilineni, Sebastian Fernandez‐Pol, (unknown), Robert S. Negrin, Parveen Shiraz, Melody Smith, (unknown), Wen-Kai Weng, Vanessa E. Kennedy, Saurabh Dahiya, Lori Muffly, David B. Miklos, Matthew J. Frank, Hitomi Hosoya, Surbhi Sidana	0
2	Early detection, clinicopathological subtyping, and prognosis prediction for endometrial cancer patients using fragmentomics liquid biopsy assay 2025 ·ESMO Open ·Qing Rao, Hui Zhou, Wen-Kai Weng, Yazhou He, (unknown), Pingping He, Wanxiangfu Tang, (unknown), Xiaodan Zhu, Dan Zhu, (unknown), Xue Wu, (unknown), Zhixiong Lin, Bingnan Zhang	1
3	Comparison of Post-Transplant Cyclophosphamide Vs Methotrexate and Calcineurin Inhibitor for Gvhd Prophylaxis in Myeloablative Transplants with HLA Matched Donors 2025 ·Transplantation and Cellular Therapy ·Vanessa E. Kennedy, Parveen Shiraz, Sally Arai, Laura Johnston, Andrew R. Rezvani, Judith A. Shizuru, Everett Meyer, (unknown), Lekha Mikkilineni, Surbhi Sidana, Hitomi Hosoya, Wen-Kai Weng, Saurabh Dahiya, (unknown), Melody Smith, Robert S. Negrin, David B. Miklos, Lori Muffly	0
4	Correlation of mesothelin (MSLN) expression measured by RNA sequencing (RNASeq) and immunohistochemistry (IHC) in MSLN-expressing tumors. 2025 ·Journal of Clinical Oncology ·J. Randolph Hecht, Patrick Grierson, Theodore H. Welling, Kristen Spencer, Antonious Hazim, Jong Chul Park, Matthew L. Ulrickson, Kedar Kirtane, Hemant S. Murthy, Sandip Pravin Patel, Jennifer M. Specht, Wen-Kai Weng, Marcela V. Maus, David G. Maloney, (unknown), Julian R. Molina, Armen Mardiros, Maria Pia Morelli, John S. Welch, Diane M. Simeone	0
5	BEAM-201 for the Treatment of Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL): Initial Data from the Phase (Ph) 1/2 Dose-Exploration, Dose-Expansion, Safety, and Efficacy Study of Multiplex Base-Edited Allogeneic Anti-CD7 CAR-T-Cells 2024 ·Blood ·Caroline Diorio, Paul Shaughnessy, Nosha Farhadfar, Anjali S. Advani, Wen-Kai Weng, Hagop Youssoufian, (unknown), Forst E. Brown, (unknown), Lalit Kumar, Jigar Patel, Shangbin Liu, Sunita Goyal, Amy Simon, Alex C. Minella, David T. Teachey	3
6	EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A02 loss of heterozygosity (LOH). 2024 ·Journal of Clinical Oncology* ·Julian R. Molina, Diane M. Simeone, (unknown), Theodore H. Welling, Kedar Kirtane, Patrick Grierson, Maria Pia Morelli, J. Randolph Hecht, Sandip Pravin Patel, Frederick L. Locke, Wen-Kai Weng, Marwan Fakih, (unknown), (unknown), (unknown), John S. Welch, Marcela V. Maus, David G. Maloney, William Y. Go, Salman R. Punekar	3
7	Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation 2018 ·Blood Advances ·Lori Muffly, Kevin Sheehan, Randall Armstrong, Kent P. Jensen, Keri Tate, Andrew R. Rezvani, David B. Miklos, Sally Arai, Judith A. Shizuru, Laura Johnston, Everett Meyer, Wen-Kai Weng, Ginna G. Laport, Robert S. Negrin, S Strober, Robert Lowsky	29
8	Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2 2015 ·Nature Genetics ·Alexander Ungewickell, Aparna Bhaduri, Eon J. Rios, Jason Reuter, Carolyn Lee, Angela Mah, Ashley Zehnder, Robert S. Ohgami, Shashikant Kulkarni, Randall Armstrong, Wen-Kai Weng, Dita Gratzinger, Mahkam Tavallaee, Alain H. Rook, M Snyder, Hyun Soo Kim, Paul A. Khavari	195
9	Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis 2013 ·Cell Death and Differentiation ·Walter Hanel, N D Marchenko, Suheng Xu, Stephen Yu, Wen-Kai Weng, Ute M. Moll	219
10	Cancer Vaccines and T Cell Therapy 2012 ·Biology of Blood and Marrow Transplantation ·Katayoun Rezvani, Joshua Brody, Holbrook E. Kohrt, Aaron C. Logan, Ranjana H. Advani, Debra K. Czerwinski, Wen-Kai Weng, Robert S. Negrin, Victoria Carlton, Malek Faham, Ronald Levy, John Barrett	8
11	Transcriptome sequencing in Sézary syndrome identifies Sézary cell and mycosis fungoides-associated lncRNAs and novel transcripts 2012 ·Blood ·Carolyn Lee, Alexander Ungewickell, Aparna Bhaduri, Kun Qu, Dan E. Webster, Randall Armstrong, Wen-Kai Weng, Cody J. Aros, Angela Mah, Richard Chen, Meihong Lin, Uma Sundram, Howard Y. Chang, Markus Kretz, Youn H. Kim, Paul A. Khavari	64
12	Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation 2011 ·Biology of Blood and Marrow Transplantation ·Ginna G. Laport, Kevin Sheehan, Jeanette Baker, Randall Armstrong, Ruby M. Wong, Robert Lowsky, Laura Johnston, Judith A. Shizuru, David B. Miklos, Sally Arai, Jonathan Benjamin, Wen-Kai Weng, Robert S. Negrin	112
13	Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma 2009 ·Leukemia & lymphoma ·John M. Timmerman, Julie M. Vose, Debra K. Czerwinski, Wen-Kai Weng, Diane E. Ingolia, (unknown), Dan W. Denney, Ronald Levy	28
14	The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells 2008 ·Blood ·Mohammad Luqman, (unknown), (unknown), Georgios Georgakis, Anu Cherukuri, Jocelyn Holash, Cheryl Goldbeck, Xiaomei Xu, Edward E. Kadel, Sang Hoon Lee, Sharon L. Aukerman, Bahija Jallal, Natasha Aziz, Wen-Kai Weng, William G. Wierda, Susan O’Brien, Anas Younes	81
15	FcγR IIIa polymorphism and anti-idiotype humoral immune response predict clinical outcome in follicular lymphoma patients receiving idiotypic vaccination 2004 ·Journal of Clinical Oncology ·Wen-Kai Weng, Debra K. Czerwinski, Ronald Levy	2
16	Differential induction of DNA-binding activities following CD19 cross-linking in human B lineage cells 1997 ·The Journal of Immunology ·Wen-Kai Weng, Nisha Shah, Darin P. O’Brien, Brian Van Ness, Tucker W. LeBien	15
17	Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production. 1996 ·Journal of Clinical Investigation ·Andrew Plump, Sandra K. Erickson, Wen-Kai Weng, Jacqueline S. Partin, J L Breslow, D. L. Williams	161
18	Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and & epsilon;1/lsquo;null genotype‡ 1992 ·European Journal of Clinical Investigation ·Giso Feussner, Harald Funke, Wen-Kai Weng, Gerd Assmann, Karl J. Lackner, R. Ziegler	23
19	Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. 1991 ·Journal of Clinical Investigation ·Arnold von Eckardstein, (unknown), M. Sandkamp, Wen-Kai Weng, Harald Funke, Gerd Assmann	69
20	Selection of a Brucella vaccine strain of low residual virulence by chemical mutagenesis 1989 ·Journal of Medical Microbiology ·(unknown), (unknown), (unknown), Wen-Kai Weng, (unknown)	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact